- CEL-SCI Corp and the AIDS ReSEARCH Alliance have completed a PhaseI trial of the HGP-30 AIDS vaccine. The study demonstrated that the vaccine was safe in 24 HIV-infected patients (it has also been shown to be safe and immunogenic in 39 uninfected volunteers). The vaccine will now be evaluated in combination with Immunex' Leukine (sargramostim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze